HERBALIFE LTD. Q3 FY2026 earnings call

• Strategic Focus on Distributor Success: Interim CEO John DeSimone emphasized that Herbalife’s core strategy is enabling distributor success through tailored support, products, and technology, leveraging the entrepreneurial spirit of over 3 million distributors globally.
• Nutrition Club Vertical: The company plans to establish a dedicated internal organization to support its 64,000 nutrition clubs globally. This initiative aims to provide better tools, specific products, and coordinated training to boost productivity, noting that U.S. club productivity has increased over 10% year-over-year.
• Technology Platform Expansion: Management is building a common modular technology foundation to replace disparate apps and manual processes. The goal is to capture at least 50% of global consumer transactions within this ecosystem within three years. The '24 Games' digital program will launch in Q1 2027 as the first module.
• Bionic Brand Growth: Bionic is being expanded from a personalized nutrition business into a premium health and wellness brand covering sports performance and healthy lifespan. It will absorb the 'Life.io' brand and serve as a pathway for new entrepreneurs, aiming to attract segments that may not resonate with the main Herbalife brand.
• GLP-1 Opportunity: Management identified a significant opportunity to position existing products alongside GLP-1 medications, focusing on protein and energy needs rather than just weight management, without requiring immediate new product development.
• Operational Efficiency: Gross profit margin decreased 40 basis points to 77.3%, impacted by country mix, input costs, and higher other costs, partially offset by pricing benefits. Operating cash flow rose 27% year-over-year to $298 million YTD.

The company reported consolidated net sales of $1.4 billion, representing a 6% increase year-over-year on a reported basis and a 7.6% increase on a constant currency basis. Adjusted EBITDA was $182 million, with an adjusted EBITDA margin of 13.5%, up 70 basis points year-over-year. Regionally, Asia Pacific led growth with constant currency net sales up 26%, driven primarily by India, which saw a 39% increase in net sales (52% in local currency) due to strong volume growth and favorable tax changes. Latin America grew 5.1% in constant currency and 9% on a reported basis. North America increased 1.7%, aided by revenue recognition timing shifts from the first quarter. Conversely, EMEA and China experienced declines, partially offsetting gains in other regions.

• Q4 2026 Net Sales: Reported guidance maintained at 0.5% to 4.5% year-over-year growth, including a 200 basis point currency headwind. Constant currency guidance set at 2.5% to 6.5% growth.
• Q4 2026 Adjusted EBITDA: Reported range set at $145 million to $165 million; constant currency range set at $155 million to $175 million.
• Full Year 2026 Net Sales: Raised reported guidance to 4.9% to 5.9% year-over-year growth. Constant currency guidance raised to 5.3% to 6.3% growth.
• Full Year 2026 Adjusted EBITDA: Reported range maintained at $670 million to $690 million. Constant currency range raised to $700 million to $720 million.
• Capital Expenditures: FY2026 CapEx narrowed to $55 million to $65 million (previously wider). Capitalized/prepaid SAS implementation costs narrowed to $35 million to $45 million.

• Foreign Exchange Volatility: FX remained a significant headwind, contributing 160 basis points to the negative impact on both net sales and adjusted EBITDA in Q3, exceeding the 100 basis point headwind included in prior guidance.
• Margin Pressure: Input costs related to self-manufacturing and sourcing, along with unfavorable country mix, pressured gross profit margins. Management noted the path to further margin expansion would be gradual and monitored closely for 2027.
• Technology Adoption Uncertainty: The success of the new modular customer engagement platform depends on distributor adoption. Usage determines value, and low current usage of legacy tools like 'Protocol' poses a risk to realizing full platform potential.
• Execution Risk on New Initiatives: Launching the Bionic brand expansion and integrating Life.io carries execution risks regarding market reception and cannibalization or synergy realization within the broader portfolio.

Q: Analyst asked about strategic priorities for GLP-1 coexistence and updates on Bionic, Protocol, and Life.io brands.

A: DeSimone stated that current products can effectively coexist with GLP-1 users by positioning them for protein and energy needs, viewing this as a major growth opportunity without needing new SKUs immediately. Regarding brands, he clarified that Bionic is a top priority, expanding beyond personalized nutrition to include sports and lifestyle, while absorbing Life.io into the Bionic umbrella to avoid brand fragmentation. Protocol remains in beta with low usage; it will continue on a parallel track but is not the sole focus, as management builds a broader, customizable modular platform to support diverse distributor models starting with '24 Games' in Q1 2027.